Saggio di commento all'Assioco pseudoplatonico

Nell'introduzione sono presentate le testimonianze antiche e bizantine sul dialogo; successivamente sono discusse le posizioni assunte dalla critica negli ultimi due secoli in merito alle questioni di attribuzione e datazione; infine è tracciato un breve profilo della letteratura consolatoria al fine di mostrare le peculiarità con cui il dialogo si inserisce nel genere. Segue un commento lemmatico continuo sulla prima parte del dialogo, scandita in quattro sezioni (364a1-65a2; 365a2-65c9; 365c10-66b2; 366b3-67a2); sono presi in esame problemi di natura linguistica, di critica testuale, storico-filosofici, letterari e più generalmente esegetici

Nota a Luciano, Ippia 2

This article proposes reading ἱκανώτατος, instead of the transmitted πιθανώτατος, at Luc. Hipp. 2, where the text is speaking of Tales’ cleverness

The Magnetic Spectrometer Prisma at Lnl

The magnetic spectrometer PRISMA [1,2,3] has been recently installed at LNL. It has been designed to be used with heavy-ion beams accelerated at energies up to E = 5-10 AMeV by means of the Tandem-ALPI accelerator complex of the Laboratori Nazionali di Legnaro. The next operation of the new superconductive injector PIAVE and its coupling with the ALPI Linac will allow to extend the nuclear physics studies in the A=100-200 mass region. Moreover, PRISMA i

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication

[Platone], Assioco. Saggio introduttivo, edizione critica, traduzione e commento

“Non si deve temere la morte”. Socrate cerca di aiutare Assioco a superare la paura della morte attraverso una serie di argomenti di diversa natura. Nel corso di questo dialogo consolatorio emerge un confronto tra due opposte concezioni della realtà: il superamento della paura della morte comporta una presa di posizione sul problema della natura dell’uomo e induce a riflettere sulla relazione tra ricerca della felicità e ricerca della verità. Questo libro offre un lavoro globale sull’Assioco pseudo-platonico. Il saggio introduttivo colloca il dialogo in un contesto storico preciso. La nuova edizione critica è fondata su uno studio completo della tradizione, mentre la nuova traduzione italiana e l’ampio commento aiutano il lettore ad affrontare i numerosi problemi che questo testo pone

Due note critico-testuali a [Chio] Ep. 16

This article proposes reading τῆς φύσεως τῶν ὄντων instead of τῆς φύσεως τῶν λόγων at [Chio] Ep. 16, 4 and οὔτε πείθεσθαι βραδέως περὶ αὐτῆς instead of οὔτε πείθεσθαι ῥᾳδίως περὶ αὐτῆς at [Chio] Ep. 16,

No Country for Old Men (Hom. ο 409-411)

International audienceThe description of the Island of Syria, Eumaeus’ homeland, in Book 15 of the Odyssey, has always been regarded as one of the many fanciful descriptions of an ideal place. However, this description may be seen also in another perspective. Actually, it is possible that it preserves the memory of the ancient practice of eliminating the elderly members of a community.La description de l’île de Syria, patrie d’Eumée, dans le XVe livre de l’Odyssée, a toujours été envisagée comme l’une des nombreuses représentations fantastiques d’un lieu idéal. Toutefois, on peut la considérer même d’un autre point de vue. En effet, il est possible qu’elle nous préserve la mémoire de l’ancienne pratique d’éliminer les vieux membres d’une communauté

Affermare l'immortalità dell'anima: il testo dell'Assioco tra Academici e Platonici

At the end of the Axiochus Socrates vigorously states that the soul is immortal (τοῦτο μόνον ἐμπέδως οἶδα ὅτι ψυχὴ ἅπασα ἀθάνατος· ἡ δὲ ἐκ τοῦδε τοῦ χωρίου μετασταθεῖσα καὶ ἄλυπος). However, this statement is in contrast with Socrates’ previous profession of ignorance in such matters. This contradiction raises the suspicion that the text is corrupted and possibly interpolated by a dogmatic Platonist. For this reason the author attempts the correction τοῦτο μόνον ἐμπέδως οἶδα ὅτι, ψυχὴ ἅπασα ἀθάνατος, [ἡ δὲ] ἐκ τοῦδε τοῦ χωρίου μετασταθεῖσα καὶ ἄλυπος. The XVIth century case of Étienne Dolet is a clear example of the ideological tensions that this dialogue could give rise t

Arcesilao e Numenio: note a fr. 25 des Places (= Eus. Praep. Ev. XIV, 5, 12-13 des Places)

This article concerns with three textual notes on Numenius fr. 25 Des Places, 15-21: 1) it postulates that the sequence ὧν ὑπὸ μὲν Κράντορος πιθανουργικός, ὑπὸ Διοδώρου δὲ σοφιστής, ὑπὸ δὲ Πύρρωνος is affected by a lacune which contained a reference to Theophrastus; 2) then it proposes reading οὐδὲν ὸ in the very probably corrupted and much-disputed passage ἐγένετο παντοδαπὸς καὶ ἴτης καὶ οὐδὲν. ὃ καὶ ἐλέγετο κτλ.; 3) finally it proposes reading ἐγένετο instead of ἐλέγετο in the previous passage